GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Phase 4 Terminated 15 enrolled University at Buffalo AstraZeneca · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Timeline

Start: 2017-01-10
Primary completion: 2019-07
Completion: 2019-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	2 mg	—

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications